Company News

Share this article:

Abbott Laboratories sued Johnson & Johnson's Centocor unit over an alleged patent infringement. Centocor‘s Simponi (golimumab) would compete with Abbott's Humira, a rheumatoid arthritis treatment and the company's best selling drug – at $4.5 billion in global sales for 2008 – according to a Bloomberg report. Centocor's Simponi will be marketing by Schering-Plough outside of the US.

 

AstraZeneca filed a supplemental new drug application (sNDA) with the FDA for an expanded indication on Nexium. The new indication is for gastric and duodenal ulcers stemming from low-dose aspirin use. Nexium, a heartburn drug, is currently indicated for the treatment of acid reflux disease, as well as for risk reduction in the occurrence of gastric ulcers associated with continuous non-steroidal anti-inflammatory drug therapy.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.